8-K: McKesson Reports Strong Fiscal 2025 Results, Announces Medical-Surgical Solutions Separation

McKesson Corporation announces strong fiscal 2025 results with revenue growth and adjusted earnings per diluted share increase, alongside plans to separate its Medical-Surgical Solutions segment.

Summary

• McKesson Corporation reported its fiscal 2025 fourth quarter and full-year results on May 8, 2025.
• Consolidated revenues for the fourth quarter increased by 19% to $90.8 billion.
• Earnings per diluted share for the fourth quarter increased to $10.01, a $3.99 increase.
• Adjusted earnings per diluted share for the fourth quarter increased by 64% to $10.12.
• Full-year consolidated revenues increased by 16% to $359.1 billion.
• Full-year earnings per diluted share increased to $25.72, a $3.33 increase.
• Full-year adjusted earnings per diluted share increased by 20% to $33.05.
• Cash flow from operations was $6.1 billion, and free cash flow was $5.2 billion for the full year.
• McKesson is establishing a fiscal 2026 adjusted earnings per diluted share guidance range of $36.75 to $37.55, indicating 11% to 14% forecasted growth.
• Excluding fiscal 2025 net gains associated with McKesson Ventures' equity investments, the guidance range indicates 13% to 16% forecasted growth.
• McKesson is reaffirming its long-term adjusted earnings per diluted share growth target of 12% to 14%.
• The company is updating its long-term adjusted segment operating profit growth target for U.S. Pharmaceutical from 5% to 7% to a new target of 6% to 8%.
• McKesson announced its intention to separate its Medical-Surgical Solutions segment into an independent company.
• The separation is expected to enhance the strategic opportunity and operational focus of both companies, unlocking value for McKesson shareholders.
• McKesson returned $3.5 billion of cash to shareholders, including $3.1 billion in stock repurchases and $345 million in dividend payments.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and strategic initiatives. The planned separation of the Medical-Surgical Solutions segment is viewed favorably as a move to unlock shareholder value. However, the inherent risks associated with forward-looking statements and industry-specific challenges temper the overall sentiment.

Positives

• Strong revenue growth in both the fourth quarter and full year.
• Significant increase in adjusted earnings per diluted share.
• Healthy cash flow from operations and free cash flow.
• Positive outlook for fiscal 2026 with expected earnings growth.
• Strategic decision to separate the Medical-Surgical Solutions segment to unlock shareholder value.
• Continued advancement and expansion of oncology and biopharma platforms.
• Commitment to returning cash to shareholders through stock repurchases and dividends.
• McKesson's biopharma services platform helped patients save more than $10 billion on brand and specialty medications in the past year.
• McKesson's biopharma services platform helped prevent 12 million prescriptions from being abandoned due to affordability challenges.
• McKesson's biopharma services platform helped patients access their medicine more than 100 million times.

Negatives

• The International segment reported a segment operating loss of $213 million for the full year, although adjusted segment operating profit increased by 13%.

Risks

• The company acknowledges risks and uncertainties that could cause actual results to differ materially from forward-looking statements, including legal disputes, cybersecurity incidents, and changes in healthcare laws.
• The separation of the Medical-Surgical Solutions segment may not be executed in a manner that maximizes shareholder value.
• The company is subject to frequently changing, extensive, complex, and challenging healthcare and other laws.
• The company might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted.
• The company might be adversely impacted by conditions and events outside of its control, such as widespread public health issues, natural disasters, and geopolitical factors.

Future Outlook

McKesson anticipates fiscal 2026 Adjusted Earnings per Diluted Share of $36.75 to $37.55, reflecting strong operating momentum across the businesses, strength of its financial position, and a balanced approach to capital deployment. The company reaffirms its long-term Adjusted Earnings per Diluted Share growth target of 12% to 14% and updates its long-term Adjusted Segment Operating Profit growth target for U.S. Pharmaceutical to 6% to 8%.

Management Comments

• Brian Tyler, chief executive officer, stated that McKesson delivered strong fourth quarter performance with revenue growth of 19% and Adjusted Earnings per Diluted Share growth of 64%.
• Mr. Tyler also mentioned that the strength of the core pharmaceutical distribution business, expansion of the Oncology platform, and continued growth of differentiated biopharma solutions businesses led to strong results.
• Mr. Tyler stated that disciplined capital deployment and portfolio management are hallmarks of McKesson's strategy.
• Mr. Tyler believes that the separation of the Medical-Surgical Solutions segment will deliver sustainable long-term growth for both companies.

Industry Context

McKesson's announcement reflects a broader trend in the healthcare industry of companies focusing on core competencies and higher-growth areas. The separation of the Medical-Surgical Solutions segment allows McKesson to concentrate on its pharmaceutical distribution, oncology, and biopharma solutions businesses, aligning with the industry's shift towards specialized healthcare services.

Comparison to Industry Standards

• McKesson's revenue growth of 16% for the fiscal year is strong compared to competitors in the pharmaceutical distribution industry.
• The adjusted earnings per diluted share growth of 20% also indicates strong performance relative to industry peers.
• The planned separation of the Medical-Surgical Solutions segment is a strategic move similar to actions taken by other large healthcare companies to streamline operations and focus on core businesses.
• Companies like Cardinal Health and AmerisourceBergen are also major players in the pharmaceutical distribution industry, and their financial performance and strategic decisions can be compared to McKesson's.
• McKesson's focus on oncology and biopharma solutions aligns with the industry's increasing emphasis on specialty pharmaceuticals and personalized medicine.

Stakeholder Impact

• Shareholders are expected to benefit from the increased strategic focus and potential value creation resulting from the Medical-Surgical Solutions separation.
• Customers and partners can expect enhanced service and solutions from both McKesson and the independent Medical-Surgical Solutions company.
• Patients may benefit from improved access to quality care and affordable medications through McKesson's initiatives.
• Employees of both McKesson and the Medical-Surgical Solutions company will be impacted by the organizational changes and new strategic directions.

Next Steps

• McKesson will provide more information on the form and timing of the Medical-Surgical Solutions separation as the process progresses.
• McKesson management will participate in the BofA Securities 2025 Healthcare Conference on May 13, 2025.
• The company will continue to execute its strategic priorities and target investments to accelerate growth and modernize the portfolio.

Key Dates

Keywords

McKesson, financial results, earnings, revenue, Medical-Surgical Solutions, separation, guidance, oncology, biopharma, pharmaceutical, healthcare